Peginterferon-α-2a (40kD): A review of its use in chronic hepatitis B

Drugs

Volumn 69, Issue 18, 2009, Pages 2633-2660

  Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; MACROGOL; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS DNA;

AGE DISTRIBUTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANTIVIRAL ACTIVITY; APPETITE; ARTHRALGIA; CHRONIC DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; EMBASE; FATIGUE; FEVER; FOLLOW UP; GENOTYPE; HEADACHE; HEPATITIS B; HUMAN; IMMUNOMODULATION; INJECTION SITE REACTION; KIDNEY FAILURE; MEDLINE; MONOTHERAPY; MYALGIA; NAUSEA; NEUTROPENIA; PHARMACODYNAMICS; PREDICTION; PRURITUS; REVIEW; SEROCONVERSION; SEX DIFFERENCE; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VIRUS LOAD; VIRUS REPLICATION;

ADULT; AGE FACTORS; ANTIVIRAL AGENTS; DNA, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG CARRIERS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON-ALPHA; LAMIVUDINE; PATIENT SELECTION; POLYETHYLENE GLYCOLS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

HEPATITIS B VIRUS;

EID: 71849105362     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11203660-000000000-00000     Document Type: Review

References (85)

1. Lok ASF, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009 Sep; 50 (3): 1-36.
2. Sorrell MF, Belongia EA, Costa J. National Institutes of Health consensus development conference statement: management of hepatitis B. Hepatology 2009 May; 49 (5 Suppl.): S4-12.
3. Liaw Y-F, Leung N, Kao J-H, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2 (3): 263-283
4. McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology 2009 May; 49 (5 Suppl.): S45-55.
5. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009 Feb; 50 (2): 227-242
6. Roche. Pegasys (peginterferon alfa-2a): scientific discussion document [online]. Available from URL: http://www.emea. europa.eu/humandocs/PDFs/EPAR/ pegasys/199602en6.pdf [Accessed 2009 Jun 10].
7. Liang TJ. Hepatitis B: the virus and disease. Hepatology 2009 May; 49 (5 Suppl.): S13-21.
8. Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001; 40 (7): 539-551
9. Hoffmann-La Roche Inc. Pegasys® (peginterferon alfa-2a): US prescribing information [online]. Available from URL: http://www.rocheusa.com/ products/pegasys/pi.pdf [Accessed 2009 Jun 10].
10. Perrillo R. Benefits and risks of interferon therapy for he-patitis B. Hepatology 2009 May; 49 (5 Suppl.): S103-11.
11. Colombatto P, Civitano L, Bizzarri R, et al. A multiphase model of the dynamics of HBV infection in HBeAg-negative patients during pegylated interferon-a2a, lamivudine and combination therapy. Antivir Ther 2006; 11 (2): 197-212.
12. Marcellin P, Lau GKK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004 Sep 16; 351 (12): 1206-1217
13. Zhang H-Y, Li J, Hui C-K, et al. Inhibition of viral re-plication with pegylated interferon alpha-2a increases IL-17 in chronic hepatitis B [abstract no. 934]. Hepatology 2007 Oct; 46 (4 Suppl. 1): 652.
14. Roche. Pegasys (peginterferon alfa-2a): EU summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/ humandocs/PDFs/EPAR/ pegasys/H-395-PI-en.pdf [Accessed 2009 Jun 10].
15. Sulkowski M, Wright T, Rossi S, et al. Peginterferon alfa-2a does not alter the pharmacokinetics of methadone inpatients with chronic hepatitisCundergoing methadone maintenance therapy. Clin Pharmacol Ther 2005 Mar; 77 (3): 214-224
16. Cooksley WG, Piratvisuth T, Lee SD, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003 Jul; 10 (4): 298-305.
17. Lau GKK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005 Jun 30; 352 (26): 2682-2695
18. Chen X-F, Chen X-P, Huang J, et al. Comparison of peginterferon alfa-2a versus entecavir in patients with HBeAg-positive chronic hepatitis B with mildly elevated alanine aminotransferase levels [abstract]. 44th Annual Meeting of the European Association for the Study of the Liver; 2009 Apr 22-26; Copenhagen.
19. Hou J, Sun J, Xie Q, et al. Efficacy and safety of peginterferon alfa-2a versus adefovir dipivoxil in treating lamivudine resistant HBeAg positive CHB: an interim analysis of a prospective randomized study [abstract no. 978]. Hepatology 2008 Oct; 48 (4): 745-746
20. Chen XP, Chen X-F, Huang J, et al. Extending peginterferon alfa-2a therapy in patients with HBeAg-positive chronic hepatitis B who did not achieve a response at week 48 can lead to HBeAg seroconversion and HBsAg clearance [abstract no. 410]. Hepatology 2009 Oct; 50 (4 Suppl.): 499A.
21. Hou J, Sun J, Xie Q, et al. On-treatment quantification of HBsAg in difficult-to-treat patients with lamivudine resistance can help identify those most likely to acheive sustained post-treatment response to peginterferon alfa-2a rescue therapy [abstract no. 392]. Hepatology 2009 Oct; 50 (4 Suppl.): 490A.
22. Lau GKK, Piratvisuth T, Luo KX, et al. Durability of re-sponse and occurrence of late response to peginterferon alpha-2a (40KD) [Pegasys] one year post-treatment in patients with HBeAg-positive chronic hepatitis B [abstract no. 50]. J Hepatol 2006 Jan 1; 44 (Suppl. 2): 23-24
23. Piratvisuth T, Lau G, Chao Y-C. Sustained response to pe-ginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. Hepatol Int 2008; 2: 102-110
24. Xu D-Z, Xie Y, Wei L, et al. Efficacy and safety of peginterferon alfa-2a in Chinese patients with HBeAg-positive chronic hepatitis B [abstract]. 43rd Annual Meeting of the European Association for the Study of the Liver; 2008 Apr 23-27; Milan.
25. Zhu Y-Y, Dong J, Chen Y-T, et al. Extended treatment with peginterferon alfa-2a benefits patients with HBeAg-positive chronic hepatitis B with a partial response after 48 weeks of therapy: clinical experience from a Chinese center [abstract no. 453]. Hepatology 2009 Oct; 50 (4 Suppl.): 519A.
26. Zhu Y-Y, Dong J, Chen Y-T, et al. Extending the treatment duration of peginterferon alfa-2a therapy to 72 weeks increases the rate of HBEAG seroconversion in patients with HBEAG-positive chronic hepatitis B [abstract]. 44th Annual Meeting of the European Association for the Study of the Liver; 2009 Apr 22-26; Copenhagen.
27. Suh D, Lee HC, Byun K, et al. A multicenter, open-label study of efficacy and safety of peginterferon alfa-2a (40KD) in Korean patients with HBeAg-positive CHB harboring lamivudine-resistant YMDD mutants [abstract no. 981]. Hepatology 2008 Oct; 48 (4 Suppl.): 747.
28. Rezzonico L,Galdame O,Frider B, et al. Twenty-four weeks therapy with peginterferon alfa-2a is similar to 48 weeks therapy in patients with HBeAg positive chronic hepatitis B and good predictors of response [abstract no. 978]. Hepatology 2007 Oct; 46 (4 Suppl. 1): 673.
29. Hui C-K, Lai LSW, Lam P, et al. 48 weeks pegylated interferon alpha-2a is superior to 24 weeks of pegylated interferon alpha-2b in achieving hepatitis B e antigen seroconversion in chronic hepatitis B infection. Aliment Pharmacol Ther 2006 Apr 15; 23 (8): 1171-1178
30. Janssen HL, Rijckborst V, Cakaloglu Y, et al. 48 weeks of peginterferon alfa-2a alone or in combination with riba-virin for HBeAg-negative chronic hepatitis B: addition of ribavirin does not improve response rates [abstract no. 991]. Hepatology 2008 Oct; 48 (4 Suppl.): 752.
31. Piccolo P, De Melia L, Bandiera F, et al. Peginterferon alpha-2a plus adefovir dipivoxil vs peginterferon alpha-2a monotherapy for 48 weeks in HBeAg-negative chronic hepatitis B: final results of the PEG for B randomized multicenter trial [abstract no. 256]. Gastroenterology 2008 Apr; 134 (4 Suppl. 1): 760-761
32. Gish RG, Lau DT-Y, Schmid P, et al. A pilot study of ex-tended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B. Am J Gastroenterol 2007 Dec; 102 (12): 2718-2723
33. Marcellin P, Bonino F, Lau GKK, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alfa-2a. Gastroenterology 2009 Jun; 136 (7): 2169-2179
34. Marcellin P, Piratvisuth T, Brunetto M, et al. Virological and biochemical response in patients with HBeAg-negative chronic hepatitis B treated with peginterferon alfa-2a (40kD) with orwithout lamivudine: results of 4-year follow-up [abstract]. 43rd Annual Meeting of the European Association for the Study of the Liver; 2008 Apr 23-27; Milan.
35. Marcellin P, Piratvisuth T, Brunetto MR, et al. A finite course of peginterfeon alfa-2a results in inactive chronic hepatitis B and HBsAg clearance 5 years post-treatment in patients with HBeAg-negative disease: baseline characteristics and predictive factors of long-term response [abstract no. 387]. Hepatology 2009 Oct; 50 (4 Suppl.): 487A.
36. Fried MW, Piratvisuth T, Lau GKK, et al. HBeAg and he-patitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008 Feb; 47 (2): 428-434
37. Lau GK, Marcellin P, Brunetto M, et al. On-treatment HBsAg decline during peginterferon alfa-2a (40KD)-lamivudine in patients with HBeAg-positive CHB as a potential predictor of durable off-treatment response [abstract no. 910]. Hepatology 2008 Oct; 48 (4 Suppl.): 714.
38. Lau GKK, Marcellin P, Brunetto M, et al. On-treatment moni-toring of HBsAg levels to predict response to peginterferon alfa-2a in patients with HBeAg-positive chronic hepatitis B [abstract]. 44th Annual Meeting of the European Association for the Study of the Liver; 2009 Apr 22-26; Copenhagen.
39. Piratvisuth T, Lau GKK, Marcellin P, et al. Association between HBeAg seroconversion and sustained HBV-DNA suppression in patients treated with peginterferon alpha-2a (40KD) (Pegasys) for HBeAg-positive chronic hepatitis B (CHB) [abstract no. 49].J Hepatol 2006 Apr; 44 Suppl. 2: 23.
40. Buster EH, Hansen BE, Lau GK, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastro-enterology. Epub 2009 Sep 6.
41. Janssen HLA, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005 Jan 8; 365 (9454): 123-129
42. Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to pe-ginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009 Apr; 49 (4): 1141-1150
43. Bonino F, Marcellin P, Lau GKK, et al. Predicting response to peginterferon a-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007 May; 56 (5): 699-705.
44. Brunetto M, Bonino F, Marcellin P, et al. Kinetics of HBsAg decline in patients with HBeAg-negative chronic hepatitis B treated with peginterferon alfa-2A according to genotype and its association with sustained HBsAg clearance 4 years post-treatment [abstract no. 965]. Hepatology 2008 Oct; 48 (4 Suppl.): 740.
45. Marcellin P, Brunetto M, Bonino F, et al. In patients with HBeAg-negative chronic hepatitis B HBsAg serum levels early during treatment with peginterferon alfa-2a predict HBsAg clearance 4 years post-treatment [abstract no. 919]. Hepatology 2008 Oct; 48 (4 Suppl.): 718-719
46. Brunetto MR, Marcellin P, Bonino F, et al. HBsAg decline in HBeAg-negative patients treated with peginterferon alfa-2a is associated with sustained response up to 5 years post-treatment: patients with continuous HBsAg decline starting before week 24 achieve highest rates of response [abstract no. 452]. Hepatology 2009 Oct; 50 (4 Suppl.): 519A.
47. Rijckborst V, ter Borg MJ, Akarca US, et al. Early reduction of serum HBsAg levels in HBeAg-negative chronic hepatitis B patients achieving sustained virological response after peginterferon alfa-2A +/-ribavirin treatment [abstract no. 986]. Hepatology 2008 Oct. 48 (4 Suppl.) 749-750.
48. Rijckborst V, Hanesen BE, ter Borg M, et al. Mutations in the precore and basal core promoter regions do not influence responsiveness to pegylated interferon alfa-2a treatment for HBeAg-negative chronic hepatitis B [abstract no. 497]. Hepatology 2009 Oct; 50 (4): 542A.
49. Rijckborst V, Hansen BE, Tabak F, et al. On-treatment pre-diction of sustained response in HBeAg-negative chronic hepatitis B patients treated with pegylated interferon alfa-2a [abstract no. 492]. Hepatology 2009 Oct; 50 (4 Suppl.): 539A.
50. Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009 Apr; 49 (4): 1151-1157
51. Xu D, Chen X, Zhang W. Response patterns of Chinese patients with chronic hepatitis B who achieved HBsAg clearance through treatment with peginterferon alfa-2a [abstract no. 953]. Hepatology 2008 Oct; 48 (4 Suppl.): 734.
52. Brunetto M, Cavallone D, Moriconi F, et al. Kinetics of HBsAg decline during and following treatment of CHB: early and rapid HBsAg decline during peginterferon alfa-2A is predictive of HBsAg clearance [abstract no. 917]. Hepatology 2008 Oct; 48 (4 Suppl.): 717-718
53. Lu L, Ye D, Wang Y, et al. Correlation between HBV cccDNA and HBsAg levels and their reduction by peginterferon alfa-2a-based therapy in patients with chronic hepatitis B [abstract no. 979]. Hepatology 2008 Oct; 48 (4 Suppl.): 746.
54. Takkenberg B, Zaaijer HL, de Niet A, et al. Baseline HBsAg levels predict HBsAg loss in HBeAg negative but not in HBeAg positive chronic hepatitis B patients treated with peginterferon alfa-2a (Pegasys®) and adefovir (HEPSERA): an interim analysis [abstract no. 488]. Hepatology 2009 Oct; 50 (4 Suppl.): 536A.
55. Takkenberg B, Zaaijer HL, de Niet A, et al. High levels of HBsAg and HBV DNA during treatment predict failure for HBeAg seroconversion in HBeAg positive chronic hepatitis B patients treated with peginterferon alfa-2a (Pegasys®) and adefovir (HEPSERA): an interim analysis [abstract no. 495]. Hepatology 2009 Oct; 50 (4 Suppl.): 541A.
56. Takkenberg B, Zaaijer HL, de Niet A, et al. End of treat-ment intrahepatic hepatitis B (HBV) covalently close circular DNA (cccDNA) predicts sustained virological response in chronic hepatitis B (CHB) patients treated with peginterferon alfa-2a and adefovir [abstract no. 486]. Hepatology 2009 Oct; 50 (4 Suppl.): 535A.
57. Marcellin P, Lau GK, Zeuzem S, et al. Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a. Liver Int 2008 Apr; 28 (4): 477-485
58. Pockros PJ, Carithers R, Desmond P, et al. Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial. Am J Gastroenterol 2004 Jul; 99 (7): 1298-1305
59. Reddy KR, Wright TL, Pockros PJ, et al. Efficacy and safety of pegylated (40-kd) interferon a-2a compared with interferon a-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001 Feb; 33 (2): 433-438
60. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 Sep 26; 347 (13): 975-982
61. Heathcote EJ, Shiffman ML, Cooksley WG. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000 Dec 7; 343 (23): 1673-1680
62. Zeuzem S, Feinman SV, Rasenack J. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000 Dec 7; 343 (23): 1666-1672
63. Veenstra DL, Sullivan SD, Lai M-Y, et al. HBeAg-negative chronic hepatitis B: cost-effectiveness of peginterferon alfa-2a compared to lamivudine in Taiwan. Value Health 2008 Mar-Apr; 11 (2): 131-138
64. Sullivan SD, Veenstra DL, Chen P-J, et al. Cost-effectiveness of peginterferon alfa-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan. J Gastroenterol Hepatol 2007 Sep; 22 (9): 1494-1499
65. Veenstra DL, Sullivan SD, Dusheiko GM, et al. Cost-effectiveness of peginterferon a-2a compared with lamivudine treatment in patients with HBe-antigen-positive chronic hepatitis B in the United Kingdom. Eur J Gastroenterol Hepatol 2007 Aug; 19 (8): 631-638
66. Lacey L, Chien R-N, Chuang W-L, et al. Economic evaluation of chronic hepatitis B treatments in Taiwan. J Gastroenterol Hepatol 2008 Apr; 23 (4): 571-579
67. Lacey LF, Gane E. The cost-effectiveness of long-term anti-viral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore. J Viral Hepat 2007 Nov; 14 (11): 751-766
68. Dienstag JL. Benefits and risks of nucleoside analog therapy for hepatitis B. Hepatology 2009 May; 49 (5 Suppl.): S112-21.
69. Ghany MG, Doo EC. Antiviral resistance and hepatitis B therapy. Hepatology 2009 May; 49 (5 Suppl.): S174-84.
70. Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 2009 May; 49 (5 Suppl.): S185-95.
71. Feld JJ, Wong DKH, Heathcote EJ. Endpoints of therapy in chronic hepatitis B. Hepatology 2009 May; 49 (5 Suppl.): S96-102.
72. Andersson KL, Chung RT. Monitoring during and after antiviral therapy for hepatitis B. Hepatology 2009 May; 49 (5 Suppl.): S166-73.
73. Perrillo RP. Hepatitis B surface antigen quantification as a current-day paradox: obtaining the gold in the face of diminishing returns. Hepatology 2009 Apr; 49 (4): 1063-1065
74. Wong GL-H, Chan HL-Y. Predictors of treatment response in chronic hepatitis B. Drugs 2009; 69 (16): 2167-2177
75. Degertekin B, Lok ASF. Indications for therapy in hepatitis B. Hepatology 2009 May; 49 (5 Suppl.): S129-37.
76. Cooksley WGE. Peginterferon-a2a for the treatment of hepatitis B infection. Expert Opin Pharmacother 2005 Jul; 6 (8): 1373-1380
77. Hoffmann-La Roche. A study of Pegasys (peginterferon alfa-2a [40kD]) in patients with HBeAg positive chronic hepatitis B (CHB) [ClinicalTrials.gov identifier NCT00435825]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2009 Aug 13].
78. Terrault NA. Benfits and risks of combination therapy for hepatitis B. Hepatology 2009 May; 49 (5 Suppl.): S122-8.
79. Schering Corporation. PegIntron® (peginterferon alfa-2b): US prescribing information [online]. Available from URL: http://www.spfiles.com/ pipeg-intron.pdf [Accessed 2009 Jun 17].
80. European Medicines Agency. PegIntron: EU summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/ humandocs/PDFs/EPAR/ Pegintron/H-280-PI-en.pdf [Accessed 2009 Jun 17].
81. Liu C-J, Chuang W-L, Lee C-M, et al. HBsAg clearance continues to increase post-treatment in patients with HCV/HBV coinfection treated with peginterferon alfa-2a plus ribavirin: 1.5 year follow-up [abstract no. 419]. Hepatology 2009 Oct; 50 (4 Suppl.): 503A.
82. Kaiser S, Lutze B, Werner CR, et al. Extended treatment of HBV/HDV coinfection with peginterferon alpha 2a and adefovir or entecavir for 96 weeks versus 48 weeks leads to higher SVR rates in HDV viral replication [abstract no. 984]. Hepatology 2008 Oct; 48 (4 Suppl.): 748-749
83. Wedemeyer H, Yurdaydin C, Zachou K, et al. Pegylated interferon-alfa-2a plus adefovir combination therapy is superior to pegylated interferon-alfa-2a alone or adefovir monotherapy in reducing HBsAg levels in HDV-coinfected patients with low HBV viremia [abstract no. 981]. Hepatology 2006 Oct; 44 (4 Suppl. 1): 553-554
84. Sherman M, Shafran S, Burak K, et al. Management of chronic hepatitis C: consensus guidelines. Can J Gastroenterol 2007 Jun; 21 Suppl. C: 25-34C.
85. Janssen HLA, Buster EHCJ. Comments on the EASL practice guidelines for the management of chronic hepatitis B: controversies in interferon-based therapy [letter]. J Hepatol 2009 Jul; 51 (1): 224-226